Kirby Institute Seminar Series presents
Abstract
Induction of a protective immune response against many of the RNA viruses that circulate with large genetic diversity has been problematic. Recent evidence has suggested that a vaccine able to elicit broadly neutralising antibodies (BnAbs) will be met with the most success. This presentation focuses on the role of BnAbs in HCV infection along with the implications and challenges we face with vaccine design.